¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"HIV Infection"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cryptogenic infection
    Àẹ°¨¿°
  • defective infection
    °á¼Õ°¨¿°
  • droplet infection
    ºñ¸»°¨¿°
  • dust infection
    ¸ÕÁö°¨¿°
  • disseminated infection
    ÆÄÁ¾°¨¿°
  • double infection
    Áߺ¹°¨¿°
  • exogenous infection
    ¿ÜÀΰ¨¿°
  • endogenous infection
    ³»Àΰ¨¿°
  • enteric infection
    âÀÚ°¨¿°, Àå°¨¿°
  • ectopic infection
    µý°÷°¨¿°, À̼Ҽº°¨¿°
  • fetal infection
    žư¨¿°
  • food-borne infection
    ½Äǰ¸Å°³°¨¿°
  • fulminant infection
    Àü°Ý°¨¿°
  • generalized infection
    Àü½Å°¨¿°
  • germinal infection
    Á¾ÀÚ°¨¿°
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • vaginal infection
    Áú°¨¿°
  • wound infection
    »ó󰨿°
  • infection route
    °¨¿°°æ·Î
  • infection source
    °¨¿°¿ø, Àü¿°¿ø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hospital infection control
    º´¿ø°¨¿°°ü¸®
  • infection cycle
    °¨¿°»ç, °¨¿°°í¸®
  • laboratory infection control
    °Ë»ç½Ç°¨¿°°ü¸®
  • nosocomial infection control
    ¿ø³»°¨¿°°ü¸®
  • defective infection
    °á¼Õ°¨¿°
  • descending infection
    ÇÏÇà°¨¿°
  • disseminated infection
    ÆÄÁ¾°¨¿°
  • double infection
    Áߺ¹°¨¿°
  • droplet infection
    ºñ¸»°¨¿°
  • dust infection
    ¸ÕÁö°¨¿°
  • ectopic infection
    µý°÷°¨¿°, À̼Ұ¨¿°
  • endogenous infection
    ³»Àΰ¨¿°
  • exogenous infection
    ¿ÜÀΰ¨¿°
  • focal infection
    ±¹¼Ò°¨¿°
  • food-borne infection
    ½Äǰ¸Å°³°¨¿°
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Klebsiella infection
    Ŭ·¹ºê½Ã¿¤¶ó °¨¿°(Áõ).
  • Marburg virus infection
    ¸¶¸£ºÎ¸£±× ¹ÙÀÌ·¯½º °¨¿°.
  • Marburg virus infection
    ¸¶¸£ºÎ¸£±× ¹ÙÀÌ·¯½º °¨¿°.
  • Marburg virus infection
    ¸¶¸£ºÎ¸£±× ¹ÙÀÌ·¯ ½º°¨¿°.
  • abnormality by infection
    °¨¿°±âÇü
  • abortive infection
    ºÒ¹ß°¨¿°, ºÎÀü°¨¿°
  • abortive infection
    ºÒÇö¼º°¨¿°(ÝÕúéàõÊïæø).
  • adenovirus infection
    ¾Æµ¥³ë¹ÙÀÌ·¯½º°¨¿°.
  • aerial infection = airborne i.
    °ø±â°¨¿°(ÍöѨÊïæø)
  • aerial infection =air borne i.
    °ø±â°¨¿°(ÍöѨÊïæø), ÈíÀÔ°¨¿°(ýåìýÊïæø).
  • aerobic infection
    È£±â±Õ(¼º) °¨¿°(¡­Êïæø).
  • aerosol infection
    ºÐ¹«°¨¿°
  • air-borne infection
    °ø±â¸Å°³°¨¿°
  • anaerobic infection
    Çø±â¼º °¨¿°<Àü¿°>(¡­àõÊïæø<îîæø>).
  • anaerobic infection
    Çø±â¼º °¨¿°<Àü¿°>(¡­àõÊïæø<îîæø>).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • air-borne infection
    °ø±â¸Å°³°¨¿°
  • anaerobic infection
    Çø±â¼º °¨¿°<Àü¿°>(¡­àõÊïæø<îîæø>).
  • anaerobic infection
    Çø±â¼º °¨¿°<Àü¿°>(¡­àõÊïæø<îîæø>).
  • apparent infection
    Çö¼º°¨¿°
  • arthropod infection
    ÀýÁöµ¿¹°¸Å°³°¨¿°.
  • arthropod-borne infection
    ÀýÁöµ¿¹° ¸Å°³°¨¿°
  • ascending infection
    »óÇ༺ °¨¿°.
  • asymptomatic infection
    ¹«Áõ»ó°¨¿°(ÙíñøßÒÊïæø).
  • atrium of infection
    °¨¿°±¸(ÊïæøÏ¢).
  • bacterial infection
    ¼¼±Õ(¼º)°¨¿°.
  • bacteroides infection
    ¹ÚÅ×·ÎÀ̵¥½º °¨¿°(Áõ) (¡­Êïæøñø).
  • cervical infection
    °æºÎ°¨¿°(ÌòÝ»Êïæø).
  • chlamydial infection
    Ŭ¶ó¹Ìµð¾Æ °¨¿°
  • chronic infection
    ¸¸¼º°¨¿°(Ø·àõÊïæø)
  • community infection
    Áö¿ª°¨¿°(ÊÙ˧Ëç).
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • source of infection
    °¨¿°¿ø
  • spurious infection
    °ÅÁþ°¨¿°
  • zoonotic infection
    Àμö°øÅë°¨¿°
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • puerperal infection
    »ê¿å°¨¿°
  • pyogenic infection
    È­³ó¼º°¨¿°
  • secondary infection
    ÀÌÂ÷°¨¿°, ¼Ó¹ß°¨¿°
  • silent infection
    ¹«Áõ»ó°¨¿°
  • staphylococcal infection
    Æ÷µµ±¸±Õ°¨¿°
  • surgical infection
    ¿Ü°úÀû°¨¿°
  • systemic infection
    Àü½Å¼º°¨¿°(Áõ)
  • viral infection
    ¹ÙÀÌ·¯½º°¨¿°
  • water-borne infection
    ¼öÀμº°¨¿°, ¼öÀμºÀü¿°
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HIV Ag human immunodeficiency virus antigen
HIV-G human immunodeficiency virus-associated gingivitis
IWB indeterminate [HIV-1] Western blot; index of well being
p24 HIV antigen
URI Upper Respiratory Infection; »ó±âµµ °¨¿°
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HIV+ HIV seropositive
HIV-1 PR HIV-1 protease
MOS-HIV Medical Outcome Study HIV Health Survey
HIV Human immunodeficiency virus infection
PHI primary HIV infection
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • candidal infection
    Ä­µð´Ù °¨¿°
  • consecutive infection
    ¼Ó¹ß¼º °¨¿°
  • contact infection
    Á¢ÃË °¨¿°
    º¸±ÕÀÚ, ¶Ç´Â º´¿øÃ¼°¡ ºÎÂøÇÑ ÀǺ¹, ¹°Ç° µî¿¡ Á÷Á¢ ´ê¾Æ ÇǺγª Á¡¸·À¸·Î °¨¿°µÇ´Â Àü¿°º´ÀÇ ÀüÆÄ ¾ç½Ä. ÀÓÁú, ¸Åµ¶, Æ®¶óÄÚ¸¶ µîÀÌ ´ëÇ¥Àû ÁúȯÀÌ´Ù. ȯÀÚ³ª º¸±ÕÀÚÀÇ º´¿øÃ¼°¡ ±âħ, Àçä±â, ´ëÈ­ µîÀ» ÅëÇÏ¿© »ç¶÷ÀÇ ÄÚ³ª ¸ñ±¸¸ÛÀÇ Á¡¸·¿¡ ºñ»ê, ºÎÂøÇÏ¿© °¨¿°À» ÀÏÀ¸Å°´Â ºñ¸» °¨¿°µµ Á¢ÃË °¨¿°¿¡ Æ÷ÇÔ½ÃŲ´Ù. ÀÎÇ÷翣ÀÚ, Æó°áÇÙ µîÀÌ ÀÌ¿¡ ¼ÓÇÑ´Ù.
  • Coxsackie virus infection
    ÄÛ»çŰ ¹ÙÀÌ·¯½º °¨¿°
  • cytomegalovirus infection
    °Å´ë ¼¼Æ÷ ¹ÙÀÌ·¯½º °¨¿°
  • Denal infection
    Ä¡¾Æ °¨¿°
  • dental focal infection
    Ä¡¾Æ Á᫐ °¨¿°
    ±¹¼ÒÀûÀ¸·Î Á¡Ã³·³ »ý±ä Ä¡¾Æ °¨¿°.
  • descending infection
    ÇÏÇà °¨¿°
  • dormant infection
    Àẹ °¨¿°, ÀáÀç °¨¿°, ÈÞ¸é °¨¿°
  • double infection
    Áߺ¹ °¨¿°
  • ECHO virus infection
    ¿¡ÄÚ ¹ÙÀÌ·¯½º °¨¿°
  • enteral infection
    Àå°ü °¨¿°
  • enterobacter infection
    ¿£Å׷ιÚÅ׸£ °¨¿°
  • enterovirus infection
    Àå ¹ÙÀÌ·¯½º °¨¿°
  • erysipelothrix infection
    ´Üµ¶ °¨¿°
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
HIV enhancer Cis-acting regulatory sequences in the HIV long terminal repeat (ltr) which play a major role in induction or augmentation of HIV gene expression in response to environmental stimuli such as mitogens, phorbol esters, or other viruses. The HIV enhancer is the binding site for many cellular transcription factors including the nuclear factor nf-kappa b.
(12 Dec 1998)
HIV enteropathy Chronic, well-established diarrhoea (greater than one month in duration) without an identified infectious cause after thorough evaluation, in an HIV-positive individual. It is thought to be due to direct or indirect effects of HIV on the enteric mucosa. HIV enteropathy is a diagnosis of exclusion and can be made only after other forms of diarrhoeal illness have been ruled out.
(12 Dec 1998)
HIV envelope protein gp120 External envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. It has a molecular weight of 120,000 kD and contains numerous glycosylation sites. Gp120 binds to cells expressing CD4 cell-surface antigens, most notably t4-lymphocytes and monocytes/macrophages. Gp120 has been shown to interfere with the normal function of CD4 and is at least partly responsible for the cytopathic effect of HIV.
(12 Dec 1998)
HIV envelope protein gp160 An envelope protein of the human immunodeficiency virus that is encoded by the HIV env gene. It has a molecular weight of 160,000 kD and contains numerous glycosylation sites. It serves as a precursor for both the HIV envelope protein gp120 and the HIV envelope protein gp41.
(12 Dec 1998)
HIV envelope protein gp41 Transmembrane envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. It has a molecular weight of 41,000 and is glycosylated. The n-terminal part of gp41 is thought to be involved in cell fusion with the CD4 antigens of t4 lymphocytes, leading to syncytial formation. Gp41 is one of the most common HIV antigens detected by immunoblotting.
(12 Dec 1998)
HIV integrase <enzyme> Enzyme of the human immunodeficiency virus that is required to integrate viral DNA into cellular DNA in the nucleus of a host cell. HIV integrase is a DNA nucleotidyltransferase encoded by the pol gene.
Registry number: EC 2.7.7.-
(12 Dec 1998)
HIV integrase inhibitors Inhibitors of HIV integrase, an enzyme required for integration of viral DNA into cellular DNA.
(12 Dec 1998)
HIV long-terminal repeat Regulatory sequences important for viral replication that are located on each end of the HIV genome. The ltr includes the HIV enhancer, promoter, and other sequences. Specific regions in the ltr include the negative regulatory element (nre), nf-kappa b binding sites , sp1 binding sites, tata box, and trans-acting responsive element (tar). The binding of both cellular and viral proteins to these regions regulates HIV transcription.
(12 Dec 1998)
HIV protease <enzyme> Enzyme of the human immunodeficiency virus that is required for post-translational cleavage of gag and gag-pol precursor polyproteins into functional products needed for viral assembly. HIV protease is an aspartic protease encoded by the amino terminus of the pol gene.
Registry number: EC 3.4.23.-
(12 Dec 1998)
HIV protease inhibitors Inhibitors of HIV protease, an enzyme required for production of proteins needed for viral assembly.
(12 Dec 1998)
HIV seronegativity Immune status consisting of non-production of HIV antibodies, as determined by various serological tests.
(12 Dec 1998)
HIV seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/lav).
(12 Dec 1998)
HIV seroprevalence Studies of the number of cases where human immunodeficiency virus (HIV) is present in a specific population at a designated time. The presence in a given individual is determined by the finding of HIV antibodies in the serum (HIV seropositivity).
(12 Dec 1998)
HIV test <investigation> A test which is performed on a standard venipuncture blood specimen which detects the presence of antibodies to HIV (virus). This test may not be positive for 3 to 6 months after infection with HIV.
(27 Sep 1997)
HIV wasting syndrome <syndrome> Involuntary weight loss of greater than 10 percent associated with intermittent or constant fever and chronic diarrhoea or fatigue for more than 30 days in the absence of a defined cause other than HIV infection. A constant feature is major muscle wasting with scattered myofibre degeneration. A variety of aetiologies, which vary among patients, contributes to this syndrome.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á